Navigation Links
Shire plc: IFRS Results for the Year Ending December 31, 2007
Date:3/25/2008

(0.1)

Payment of debt issuance costs 8 (32.8) -

Proceeds from drawings under bank facility 8 1,300.0 -

Repayment of drawings under bank facility 8 (1,300.0) -

Proceeds from exercise of New River purchased

call option 141.8 -

Proceeds from issue of ordinary shares, net of

issue costs 877.3 -

Proceeds from exercise of share options 30.4 82.0

Proceeds from exercise of warrants 13.0 -

Payments to acquire shares by ESOT(1) (186.0) (92.0)

Repayment of finance lease obligations (4.3) (5.5)

Dividends paid (41.3) (32.4)

__________ __________

Net cash provided by/(used in) financing

activities 1,618.7 (48.0)

__________ __________

Net (decrease)/increase in cash and cash

equivalents (370.4) 462.5

Cash and cash equivalents at beginning of year 1,126.9 656.5

Effect of foreign currency translation 6.0 7.9

__________ __________

Cash and cash equivalents at end of year 762.5 1,126.9

__________ __________

(1) Employee Share Option Trust

1. General information Shire plc ("the Company") and its subsidiaries (collectively referred to as the "Group" or "Shire") develop and market products for specialty physicians. The Group focuses on four therapeutic areas: ADHD, gast
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
2. Shire plc: Correction Re Website
3. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
4. Shire Engages Palio
5. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
8. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
9. Shire plc: Board Changes
10. David Mott Appointed Non Executive Director at Shire
11. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015  MiMedx Group, Inc. (NASDAQ: MDXG ), ... and patent-protected processes to develop and market advanced products ... Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced ... Annual Canaccord|Genuity Growth Conference in Boston, ... CEO, William C. Taylor , President and COO, ...
(Date:8/3/2015)... -- Merck KGaA, Darmstadt, Germany ,  a ... the healthcare, life science and performance materials sectors, announced ... and launch of promising new fullerene derivatives for the ... Germany , is pursuing many projects ... Novel derivatives: highly stable, easy to process and cost ...
(Date:8/3/2015)... 2015  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... life-threatening diseases, today announced that it will host its ... on Thursday, August 13, 2015 at 4:30 p.m. Eastern ... the release of fiscal 2016 first quarter results.  A ... two hours after the call at the Investor Relations ...
(Date:8/3/2015)... Aug. 3, 2015   Intrexon Corporation (NYSE: ... half and second quarter 2015 financial results after the ... The Company will host a conference call at 5:30 ... general business update. The conference call may ... (International), and asking to join the "Intrexon Corporation Call."  ...
Breaking Biology Technology:MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2
... Hollingsworth & Vose,Company (H&V), a leading ... introduced its HVision(TM) technology platform, a collaborative,process ... of,breakthrough products. "HVision will provide H&V ... a new generation of products that exceed ...
... Corporation (OTC,Bulletin Board: KDUS.OB) announced today financial results for the ... the third quarter of 2007 and for the same period,in ... $240,227, compared to,net income of $200,335 for the same period ... third quarter of 2007 and for the same period in,2006. ...
... Stock Exchange: EVT) Reported Today Results for,the First ... OXFORD, England, November 13 /PRNewswire-FirstCall/,-- Highlights: ... - Compelling results achieved in two proof-of-concept ... 201 - Sale of the Chemical Development ...
Cached Biology Technology:H&V Introduces HVision Technology Platform to Accelerate Development of Breakthrough Products 2Cadus Reports Third Quarter 2007 Results 2Cadus Reports Third Quarter 2007 Results 3Cadus Reports Third Quarter 2007 Results 4Evotec Reports Third Quarter 2007 Results 2Evotec Reports Third Quarter 2007 Results 3Evotec Reports Third Quarter 2007 Results 4Evotec Reports Third Quarter 2007 Results 5Evotec Reports Third Quarter 2007 Results 6Evotec Reports Third Quarter 2007 Results 7Evotec Reports Third Quarter 2007 Results 8
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new Match-in-Sensor™ ... hardware encapsulated fingerprint sensor and matching solution. ... literally off the grid, isolating fingerprint image ... the fingerprint sensor to provide ultimate protection ...
(Date:7/7/2015)... 30, 2015 Research ... addition of the "Capacitive Fingerprint Sensors Patent ... To this date, fingerprint sensing technology is the ... sensors are well developed. This patent landscape focuses ... The domain of capacitive fingerprint sensors is ...
(Date:7/2/2015)... Fingerprint Cards has received an order for its ... distributor World Peace Industrial Group (WPI), part of WPG Holdings. ... . Deliveries are planned to take place during Q3 ... manufacturers in Asia . The order value ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... collective efforts to develop new drugs, the pharmaceuticals industry ... application of natural biological transformation processes. One of the ... cells in a bioreactor filled with a liquid culture ... regulations, the conditions inside the bioreactor need to be ...
... various Earth system science disciplines recently gathered to address ... in the future? Of course, possible answers to ... changing climatic conditions were to alter local vegetation, how ... Answering these questions with certainty would allow us to ...
... of BioScience, researchers present a sophisticated new ... ethanol on greenhouse gas emissions. The study, conducted by ... focuses on how mandated increases in production of the ... domestically and elsewhere. In response to the increased demand ...
Cached Biology News:Clean sampling from bioreactors 2Networking initiative to support interdisciplinary research 2Networking initiative to support interdisciplinary research 3More maize ethanol may boost greenhouse gas emissions 2
... is a recombinant protein that has been shown ... the preparation of cDNA by reverse transcription, in ... synthesis. RNA Safe Inhibitor tightly binds RNases in ... of eukaryotic RNases such as RNase A, RNase ...
...
... RNase Inhibitor (Ribonuclease inhibitor) ... enzyme used to inhibit RNase ... DNase or endonuclease activity. , ... degradation of RNA template ...
...
Biology Products: